BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C
Launched by BRISTOL-MYERS SQUIBB · Jul 7, 2011
Trial Information
Current as of June 13, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants chronically infected with Hepatitis C virus (HCV) genotype 1
- • HCV RNA viral load of ≥10,000 IU/mL at screening
- • No previous exposure to interferon formulation, ribavirin or HCV direct antiviral agent
- • Self-described as Black-African American, Latino or White-Caucasian
- • Results of a liver biopsy obtained ≤36 months prior to first treatment compensated cirrhotics with HCV liver biopsy from any time prior to first treatment.
- • Compensated cirrhotics were capped at approximately 25%
- Exclusion Criteria:
- • Evidence of decompensated liver disease
- • Documented or suspected Hepatocellular carcinoma (HCC)
- • Positive for Hepatitis B or HIV 1/HIV 2 antibody at screening
About Bristol Myers Squibb
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. With a robust portfolio of products across multiple therapeutic areas, including oncology, immunology, cardiovascular, and fibrotic diseases, BMS emphasizes cutting-edge research and a commitment to advancing medical science through clinical trials. The company is driven by a mission to provide transformative therapies, leveraging collaboration and scientific expertise to address unmet medical needs and improve patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Maywood, Illinois, United States
Miami, Florida, United States
New Orleans, Louisiana, United States
Charlotte, North Carolina, United States
Portland, Oregon, United States
Atlanta, Georgia, United States
Sacramento, California, United States
Baltimore, Maryland, United States
Bronx, New York, United States
San Antonio, Texas, United States
Atlanta, Georgia, United States
Orlando, Florida, United States
Montgomery, Alabama, United States
Baltimore, Maryland, United States
Tampa, Florida, United States
Los Angeles, California, United States
Houston, Texas, United States
Statesville, North Carolina, United States
San Juan, , Puerto Rico
Springfield, Massachusetts, United States
Chapel Hill, North Carolina, United States
San Diego, California, United States
Houston, Texas, United States
San Antonio, Texas, United States
Annandale, Virginia, United States
Ocean Springs, Mississippi, United States
Houston, Texas, United States
Long Beach, California, United States
Los Angeles, California, United States
San Diego, California, United States
San Diego, California, United States
Maimi, Florida, United States
Wellington, Florida, United States
West Palm Beach, Florida, United States
Arlington, Texas, United States
Richmond, Virginia, United States
Patients applied
Trial Officials
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials